IGC Pharma, Inc. (IGC)

Pharmaceutical Preparations · market cap $29M · as of 2026-07-18

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-11-13 (est.)

Earnings

Pipeline

programs

Upcoming events

next 90d+

Dossier

Ready

cached

IGC Pharma (IGC) is a micro-cap pharmaceutical company (~$26M market cap, ~$0.26/share) with a single disclosed clinical asset, IGC-AD1-Active, in Phase 2 for Alzheimer's Disease. The company operates with approximately 70 employees and has a critically constrained balance sheet: $1.1M cash and an estimated runway of roughly 0.9 months as of mid-July 2026.

The catalyst path

2026-11-13 (est.)Earningsimp 5/10
2026-11-15 (est.)Phase 2 · IGC-AD1-Activeimp 7/10
2026-12-31Phase 2imp 6/10

Pipeline

Asset	Phase	Indication
IGC-AD1-Active	Phase 2	Alzheimer Disease

Price & technical context

3-month

-26.9%

6-month

-40.6%

12-month

-51.3%

52-wk range

$0.19–$0.39

vs 50-day MA

-28.2%

vs 200-day MA

-31.7%

Realized vol

56.6%

Max drawdown

-59.6%

Daily closes through 2026-11-05. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

Sources & data

SEC filings — EDGAR filings for IGC (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 1 registered trial on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.